HAEMONETICS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HAEMONETICS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Mar 28, 2015 | $910.37M | May 22, 2015 |
| FY2015 | Mar 29, 2014 | $938.51M | May 22, 2015 |
| FY2015 | Mar 30, 2013 | $891.99M | May 22, 2015 |
| FY2013 | Mar 31, 2012 | $727.84M | May 22, 2014 |
| FY2012 | Apr 2, 2011 | $676.69M | May 20, 2013 |
| FY2011 | Apr 3, 2010 | $645.43M | May 22, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $1.36B | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $1.31B | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $1.17B | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $993.20M | May 20, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $748.96M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $691.55M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $615.10M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $505.50M | May 20, 2024 |
| FY2021 | Apr 3, 2021 | $81.81M | May 26, 2021 |
| FY2021 | Dec 26, 2020 | $120.26M | May 26, 2021 |
| FY2021 | Sep 26, 2020 | $105.74M | May 26, 2021 |
| FY2021 | Jun 27, 2020 | $90.03M | May 26, 2021 |
| FY2021 | Mar 28, 2020 | $113.56M | May 26, 2021 |
| FY2021 | Dec 28, 2019 | $128.05M | May 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $167.68M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $117.56M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $115.40M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $43.38M | May 20, 2024 |
| FY2021 | Apr 3, 2021 | ($11.04M) | May 26, 2021 |
| FY2021 | Dec 26, 2020 | $31.88M | May 26, 2021 |
| FY2021 | Sep 26, 2020 | $48.10M | May 26, 2021 |
| FY2021 | Jun 27, 2020 | $10.53M | May 26, 2021 |
| FY2021 | Mar 28, 2020 | $17.62M | May 26, 2021 |
| FY2021 | Dec 28, 2019 | $29.90M | May 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $221.82M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $164.88M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $156.03M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $80.75M | May 20, 2024 |
| FY2021 | Apr 3, 2021 | ($21.18M) | May 26, 2021 |
| FY2021 | Dec 26, 2020 | $40.43M | May 26, 2021 |
| FY2021 | Sep 26, 2020 | $58.78M | May 26, 2021 |
| FY2021 | Jun 27, 2020 | $11.72M | May 26, 2021 |
| FY2021 | Mar 28, 2020 | $26.01M | May 26, 2021 |
| FY2021 | Dec 28, 2019 | $40.91M | May 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $62.72M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $54.44M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $50.13M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $46.80M | May 20, 2024 |
| FY2023 | Apr 3, 2021 | $32.86M | May 22, 2023 |
| FY2022 | Mar 28, 2020 | $30.88M | May 25, 2022 |
| FY2021 | Mar 30, 2019 | $35.71M | May 26, 2021 |
| FY2020 | Mar 31, 2018 | $39.23M | May 20, 2020 |
| FY2019 | Apr 1, 2017 | $37.56M | May 22, 2019 |
| FY2018 | Apr 2, 2016 | $44.97M | May 23, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $436.79M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $431.78M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $376.68M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $340.14M | May 20, 2024 |
| FY2023 | Apr 3, 2021 | $275.22M | May 22, 2023 |
| FY2022 | Mar 28, 2020 | $282.02M | May 25, 2022 |
| FY2021 | Mar 30, 2019 | $273.47M | May 26, 2021 |
| FY2020 | Mar 31, 2018 | $316.52M | May 20, 2020 |
| FY2019 | Apr 1, 2017 | $301.73M | May 22, 2019 |
| FY2018 | Apr 2, 2016 | $317.22M | May 23, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $181.73M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $181.75M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $273.06M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $172.26M | May 20, 2024 |
| FY2023 | Apr 3, 2021 | $108.81M | May 22, 2023 |
| FY2022 | Mar 28, 2020 | $158.22M | May 25, 2022 |
| FY2021 | Mar 30, 2019 | $159.28M | May 26, 2021 |
| FY2020 | Mar 31, 2018 | $220.35M | May 20, 2020 |
| FY2019 | Apr 1, 2017 | $159.74M | May 22, 2019 |
| FY2018 | Apr 2, 2016 | $121.87M | May 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $39.28M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $38.13M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $191.33M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $96.51M | May 20, 2024 |
| FY2023 | Apr 3, 2021 | $37.04M | May 22, 2023 |
| FY2022 | Mar 28, 2020 | $48.76M | May 25, 2022 |
| FY2021 | Mar 30, 2019 | $118.96M | May 26, 2021 |
| FY2020 | Mar 31, 2018 | $74.80M | May 20, 2020 |
| FY2019 | Apr 1, 2017 | $76.14M | May 22, 2019 |
| FY2018 | Apr 2, 2016 | $102.41M | May 23, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $2.45B | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $2.20B | May 21, 2025 |
| FY2024 | Apr 1, 2023 | $1.93B | May 20, 2024 |
| FY2023 | Apr 2, 2022 | $1.86B | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $1.82B | May 25, 2022 |
| FY2021 | Mar 28, 2020 | $1.27B | May 26, 2021 |
| FY2020 | Mar 30, 2019 | $1.27B | May 20, 2020 |
| FY2019 | Mar 31, 2018 | $1.24B | May 22, 2019 |
| FY2018 | Apr 1, 2017 | $1.24B | May 23, 2018 |
| FY2017 | Apr 2, 2016 | $1.32B | May 24, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $820.84M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $959.96M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $818.00M | May 21, 2025 |
| FY2025 | Apr 2, 2022 | $749.42M | May 21, 2025 |
| FY2024 | Apr 3, 2021 | $731.67M | May 20, 2024 |
| FY2023 | Mar 28, 2020 | $587.11M | May 22, 2023 |
| FY2022 | Mar 30, 2019 | $667.87M | May 25, 2022 |
| FY2021 | Mar 31, 2018 | $752.43M | May 26, 2021 |
| FY2020 | Apr 1, 2017 | $739.61M | May 20, 2020 |
| FY2019 | Apr 2, 2016 | $721.57M | May 22, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $604.27M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $565.08M | May 21, 2025 |
| FY2025 | Apr 1, 2023 | $466.23M | May 21, 2025 |
| FY2024 | Apr 2, 2022 | $467.29M | May 20, 2024 |
| FY2023 | Apr 3, 2021 | $466.44M | May 22, 2023 |
| FY2022 | Mar 28, 2020 | $210.65M | May 25, 2022 |
| FY2021 | Mar 30, 2019 | $210.82M | May 26, 2021 |
| FY2020 | Mar 31, 2018 | $211.40M | May 20, 2020 |
| FY2019 | Apr 1, 2017 | $210.84M | May 22, 2019 |
| FY2018 | Apr 2, 2016 | $267.84M | May 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $352.17M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $360.46M | May 21, 2025 |
| FY2024 | Apr 1, 2023 | $253.17M | May 20, 2024 |
| FY2023 | Apr 2, 2022 | $202.39M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $157.98M | May 25, 2022 |
| FY2021 | Mar 28, 2020 | $78.51M | May 26, 2021 |
| FY2020 | Mar 30, 2019 | $161.42M | May 20, 2020 |
| FY2019 | Mar 31, 2018 | $266.94M | May 22, 2019 |
| FY2018 | Apr 1, 2017 | $289.92M | May 23, 2018 |
| FY2017 | Apr 2, 2016 | $316.18M | May 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $306.76M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | $178.80M | May 21, 2025 |
| FY2024 | Apr 1, 2023 | $284.47M | May 20, 2024 |
| FY2023 | Apr 2, 2022 | $259.50M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | $192.31M | May 25, 2022 |
| FY2021 | Mar 28, 2020 | $137.31M | May 26, 2021 |
| FY2020 | Mar 30, 2019 | $169.35M | May 20, 2020 |
| FY2019 | Mar 31, 2018 | $180.17M | May 22, 2019 |
| FY2019 | Apr 1, 2017 | $139.56M | May 22, 2019 |
| FY2019 | Apr 2, 2016 | $115.12M | May 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | $1.25B | May 21, 2025 |
| FY2017 | Apr 1, 2017 | $315.81M | May 24, 2017 |
| FY2016 | Apr 2, 2016 | $408.47M | Jun 1, 2016 |
| FY2015 | Mar 28, 2015 | $430.48M | May 22, 2015 |
| FY2013 | Mar 29, 2014 | $440.29M | May 22, 2014 |
| FY2012 | Mar 30, 2013 | $480.09M | May 20, 2013 |
| FY2011 | Mar 31, 2012 | $3.77M | May 22, 2012 |
| FY2011 | Apr 2, 2011 | $4.88M | May 22, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | 3 | May 21, 2025 |
| FY2025 | Mar 30, 2024 | 2 | May 21, 2025 |
| FY2025 | Apr 1, 2023 | 2 | May 21, 2025 |
| FY2024 | Apr 2, 2022 | 0 | May 20, 2024 |
| FY2021 | Apr 3, 2021 | 0 | May 26, 2021 |
| FY2021 | Dec 26, 2020 | 0 | May 26, 2021 |
| FY2021 | Sep 26, 2020 | 0 | May 26, 2021 |
| FY2021 | Jun 27, 2020 | 0 | May 26, 2021 |
| FY2021 | Mar 28, 2020 | 0 | May 26, 2021 |
| FY2021 | Dec 28, 2019 | 0 | May 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | 3 | May 21, 2025 |
| FY2025 | Mar 30, 2024 | 2 | May 21, 2025 |
| FY2025 | Apr 1, 2023 | 2 | May 21, 2025 |
| FY2024 | Apr 2, 2022 | 0 | May 20, 2024 |
| FY2021 | Apr 3, 2021 | 0 | May 26, 2021 |
| FY2021 | Dec 26, 2020 | 0 | May 26, 2021 |
| FY2021 | Sep 26, 2020 | 0 | May 26, 2021 |
| FY2021 | Jun 27, 2020 | 0 | May 26, 2021 |
| FY2021 | Mar 28, 2020 | 0 | May 26, 2021 |
| FY2021 | Dec 28, 2019 | 0 | May 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 29, 2025 | 48.22M | May 21, 2025 |
| FY2025 | Mar 30, 2024 | 50.79M | May 21, 2025 |
| FY2024 | Apr 1, 2023 | 50.45M | May 20, 2024 |
| FY2023 | Apr 2, 2022 | 51.12M | May 22, 2023 |
| FY2022 | Apr 3, 2021 | 50.87M | May 25, 2022 |
| FY2021 | Mar 28, 2020 | 50.32M | May 26, 2021 |
| FY2020 | Mar 30, 2019 | 51.02M | May 20, 2020 |
| FY2019 | Mar 31, 2018 | 52.34M | May 22, 2019 |
| FY2018 | Apr 1, 2017 | 52.26M | May 23, 2018 |
| FY2017 | Apr 2, 2016 | 50.93M | May 24, 2017 |